Pancreatic ablation: minimally invasive treatment options.
Daniele Maiettini, Giovanni Mauri, Gianluca Varano...
https://pubmed.ncbi.nlm.nih.gov/31537162/Actively Recruiting
Led by Banner Health · Updated on 2026-09-14
75
Participants Needed
7
Research Sites
26 weeks
Total Duration
Researchers are evaluating the use of a new endoscopic ultrasound-guided microwave ablation MWA device in patients with locally advanced, unresectable, or metastatic cancers such as pancreatic and liver cancer. The study aims to assess the overall success of energy delivery during treatment and to explore the safety and antitumor effects of the device. This feasibility study will provide preliminary data to guide future clinical trials and potential clinical use for difficult-to-treat tumors. Participants will receive treatment using the Creos MicroBlate Fine device guided by endoscopic ultrasound EUS. This open-label study involves a single group where all eligible participants receive the MWA procedure targeting tumors accessible via EUS through the gastric wall, such as those in the pancreas or liver. Tumors must be at least 1 cm in diameter. The treatment phase lasts up to 9 weeks from the first MWA procedure. During the study, participants will be monitored through scheduled visits for safety and effectiveness assessments up to 52 weeks after treatment begins. Researchers will evaluate procedural and clinical safety, treatment tolerability, and early antitumor effects by measuring tumor size changes and using RECIST criteria at 6 months. The overall study participation lasts up to approximately one year, including follow-up visits to track long-term outcomes and safety.
CONDITIONS
CREO - Microwave Ablation Feasibility Study
N
Neil Sharma, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Banner Health
Lead Sponsor
Creo Medical Limited
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | EUS-Guided Microwave Ablation (Creo MicroBlate™ Fine) | Percutaneous Radiofrequency Ablation (RFA) |
|---|---|---|
| What it is | A minimally invasive technique that uses endoscopic ultrasound (EUS) to guide the placement of a microwave ablation probe (Creo MicroBlate™ Fine) into tumors of the pancreas or liver for thermal destruction of cancer tissue. | A widely used, image-guided local ablation method in which a probe is inserted through the skin directly into the tumor, delivering controlled radiofrequency energy to heat and destroy cancer cells. Typically performed under CT or ultrasound guidance. |
| Role in trial | Investigational device used as the sole intervention to assess preliminary technical success, safety, and early tumor effects when delivered via EUS. | Established and guideline-endorsed ablation method for local control of unresectable or inoperable liver and selected pancreatic tumors outside of clinical trials. |
| Primary use | Ablation of locally advanced, non-resectable, or metastatic tumors in the liver or pancreas, especially in anatomic locations accessible via the GI tract but challenging for percutaneous access. | Localized thermal destruction of liver or pancreatic tumors that cannot be removed surgically, provided they are accessible via a percutaneous approach. |
| How it is given or performed | Under sedation, a flexible endoscope with an ultrasound probe is passed through the mouth to the stomach, and the microwave needle is advanced through the gastric wall into the tumor to deliver microwave energy. | Following imaging guidance, a probe is inserted through the skin directly into the tumor site, and controlled radiofrequency energy is applied for thermal ablation. Usually performed under local anesthesia or light sedation. |
| Evidence status | No published patient outcome or comparative data are available yet for this investigational approach; current evidence consists of early feasibility and safety observations from ongoing trials. | Well-established efficacy, with multiple clinical studies and meta-analyses supporting durable local tumor control and symptom relief in unresectable liver and some pancreatic cancers. Outcome data are robust in hepatocellular carcinoma, with high technical success and complication rates similar to MWA. |
| Important limitations | As an investigational procedure, outcome and comparative safety data are limited; risk of procedural complication (bleeding, perforation, infection) is possible as with any endoscopic or ablative intervention. Access is limited to tumors reachable through the stomach or duodenal wall. | Not all tumors are accessible percutaneously, especially those near large vessels or deep within the pancreas; risk of thermal injury to adjacent organs exists. Repeat procedures may be needed, and effectiveness is limited in larger or more invasive tumors. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 9 weeks
Participants receive treatment using the endoscopic ultrasound-guided microwave ablation device targeting tumors accessible through the stomach wall.
Visits as scheduled during treatment phase
Duration - Up to 52 weeks
Participants are monitored for safety, tolerability, and antitumor effects through regular visits up to 52 weeks after treatment begins.
Regular follow-up visits including imaging assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Daniele Maiettini, Giovanni Mauri, Gianluca Varano...
https://pubmed.ncbi.nlm.nih.gov/31537162/Antonio Facciorusso, Mohamed A Abd El Aziz, Nicola Tartaglia...
https://pubmed.ncbi.nlm.nih.gov/33339274/Warren A Campbell, Mina S Makary
https://pubmed.ncbi.nlm.nih.gov/39061199/Kanehiko Suwa, Toshihito Seki, Kazunori Aoi...
https://pubmed.ncbi.nlm.nih.gov/33675382/Banner Health
Lead Sponsor
Creo Medical Limited
Collaborating Sponsor